PTGX in the 13F filings
Protagonist Therapeutics Inc · CUSIP 74366E102
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 7 listed it in both
- Shares listed
- 19,775,566
- combined, among listed positions
- Reported value
- $1.7bn
- combined, at the quarter end
Among the 92 comparable managers: 14 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +4,166,001.
Managers listing PTGX in Q4 2025
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 2,649,981 shares now+1,549,160
- Wellington Management Group LLPexisting position · 3,171,423 shares now+1,262,977
- Citadel Advisors LLCexisting position · 1,126,687 shares now+888,806
- Invesco Ltdexisting position · 1,567,840 shares now+564,134
- Holocene Advisors LPnew position · 210,019 shares now+210,019
Reductions
- AllianceBernstein LPexisting position · 73,222 shares now-187,632
- Millennium Management LLCexisting position · 17,391 shares now-110,169
- Marshall Wace LLPexisting position · 1,024,925 shares now-60,639
- Farallon Capital Management LLCexisting position · 6,144,006 shares now-52,000
- Susquehanna International Group LLPexisting position · 11,762 shares now-51,426
New positions and exits
New (7)
Exited (4)
- ExodusPoint Capital Management LPwas $8.3m
- Schonfeld Strategic Advisors LLCwas $6.3m
- Brevan Howard Capital Management LPwas $505k
- Quantbot Technologies LPwas $219k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 1 | $231k | n.a. | n.a. |
| Q2 2017 | 1 | $197k | n.a. | n.a. |
| Q3 2017 | 1 | $458k | n.a. | n.a. |
| Q4 2017 | 2 | $19m | n.a. | n.a. |
| Q1 2018 | 1 | $8.7m | n.a. | n.a. |
| Q2 2018 | 2 | $6.5m | n.a. | n.a. |
| Q3 2018 | 1 | $23m | n.a. | n.a. |
| Q4 2018 | 2 | $15m | n.a. | n.a. |
| Q1 2019 | 2 | $23m | n.a. | n.a. |
| Q2 2019 | 3 | $20m | n.a. | n.a. |
| Q3 2019 | 2 | $18m | n.a. | n.a. |
| Q4 2019 | 1 | $11m | n.a. | n.a. |
| Q1 2020 | 1 | $11m | n.a. | n.a. |
| Q2 2020 | 2 | $48m | n.a. | n.a. |
| Q3 2020 | 1 | $54m | n.a. | n.a. |
| Q4 2020 | 2 | $60m | n.a. | n.a. |
| Q1 2021 | 2 | $87m | n.a. | n.a. |
| Q2 2021 | 2 | $156m | n.a. | n.a. |
| Q3 2021 | 4 | $130m | n.a. | n.a. |
| Q4 2021 | 4 | $169m | n.a. | n.a. |
| Q1 2022 | 3 | $110m | n.a. | n.a. |
| Q2 2022 | 5 | $67m | n.a. | n.a. |
| Q3 2022 | 3 | $53m | n.a. | n.a. |
| Q4 2022 | 5 | $52m | n.a. | n.a. |
| Q1 2023 | 4 | $116m | n.a. | n.a. |
| Q2 2023 | 5 | $171m | n.a. | n.a. |
| Q3 2023 | 2 | $109m | n.a. | n.a. |
| Q4 2023 | 2 | $191m | 2 | 0 |
| Q1 2024 | 5 | $248m | 4 | 1 |
| Q2 2024 | 3 | $262m | 2 | 2 |
| Q3 2024 | 3 | $286m | 2 | 1 |
| Q4 2024 | 4 | $253m | 3 | 0 |
| Q1 2025 | 4 | $354m | 3 | 1 |
| Q2 2025 | 5 | $425m | 4 | 1 |
| Q3 2025 | 8 | $790m | 8 | 0 |
| Q4 2025 | 10 | $1.3bn | 14 | 14 |
| Q1 2026 | 9 | $1.8bn | 16 | 10 |
| Q2 2026 | 7 | $1.9bn | 14 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PTGX and LLY →PTGX and JNJ →PTGX and VRTX →Choose a stock to compare with PTGX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PTGX, latest filings →Back to the 13F Explorer →